WINSTON-SALEM, N.C., June 23, 2016 /PRNewswire-USNewswire/ -- Researchers at Wake Forest Baptist Medical Center have developed a medical app for risk-evaluation and clinical support that can help emergency department personnel more efficiently determine which patients with acute chest pain can be discharged safely. 

The American College of Cardiology (ACC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on June 27 regarding the proposed Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) regulations.

A Duke LifePoint hospital in Sylva, N.C., is expanding its cardiology services by taking over an existing cardiology center in the community and hiring two new physicians as it works to provide more specialty care.

AstraZeneca is expected to lose patent protection for rosuvastatin calcium (Crestor) on July 8, but the New York Times reports that the company argues it should have seven more years of market exclusivity.

An FDA panel will meet on June 28 and vote on whether empagliflozin (Jardiance) reduces the risk of cardiovascular death in high-risk patients, Reuters reports. When the FDA approved empagliflozin in 2014 to treat patients with type 2 diabetes, the agency asked the drug’s manufacturers (Eli Lilly & Co. and Boehringer Ingelheim) to conduct a trial to prove the medication did not increase the risk of heart problems.

An analysis of patients who received endovascular therapy within 12 hours of stroke onset found that the amount of blood-brain barrier disruption on pretreatment MRIs was associated with the severity of intracranial hemorrhage.

A study by a Yale researcher has found that the use of The Watchman, a catheter-delivered device, used for patients suffering from irregular heart rhythms is more cost effective that medication.

A new study shows patients being treated for acutely high blood pressure might not fare any differently when they are treated in the hospital versus outpatient treatment.